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OBJECTIVES: Diabetes group education programs have shown better clinical 
outcomes than one-on-one programs. That effect often subsides when the 
program is discontinued. We explore the impact of a novel intervention, in a 
largely African-American population with diabetes. We assess the impact of 
leveraging patients’ natural social networks on measures of social efficacy and 
cohesion, with the assumption that those variables will support behavior change 
and mitigate modifiable risk factors. METHODS: Intervention patients  
(P2P®) were asked to recruit peers, form small clusters, and attended monthly 
diabetes education sessions. Control patients were recruited, educated and 
followed up individually. P2P® patients engaged in interactive educational 
sessions within their cluster. HbA1c, blood glucose, functional status (SF-12), 
self-efficacy (General Self-Efficacy Scale), cohesion (Perceived Cohesion Scale), 
social network characteristics (Social Network Index), and disease knowledge 
(Diabetes Knowledge Test) were recorded at baseline and followed up at  
3-months. RESULTS: Among the 136 patients recruited in the study, intervention 
patients’ (68) scores were lower on the number of active social network domains 
(1.1 vs.1.4, P=0.09), network diversity (5.6 vs. 5.9, P=0.30), and number of people  
in network (11.0 vs. 12.3, P=0.21) than controls (68), at baseline. Other baseline 
characteristics were evenly distributed between arms. After 3 months of follow-
up, the intervention group had a statistically significantly greater increase  
in values for active social network domains (1.1, P<0.01), diversity (4.52, P<0.01), 
and contacts (0.84, P<0.01) than the control group. At the second follow-up,  
(only 22 patients have reached that point so far) social network index  
values improved even further from baseline (3.1, 10.8, and 1.0, respectively), 
compared to the controls. CONCLUSIONS: The P2P® social networks intervention 
is showing improved social efficacy and integration of patients within  
their existing networks. These results inform the translation of diabetes 




RETROSPECTIVE COHORT STUDY EVALUATING LIRAGLUTIDE AND EXENATIDE 
IN A VETERAN POPULATION  
Bounthavong M1, Tran JN2, Watanabe JH3, Chen TC1 
1Veterans Affairs San Diego Healthcare System, San Diego, CA, USA, 2OptumRX, Irvine, CA, 
USA, 3Western University of Health Sciences, Pomona, CA, USA  
OBJECTIVES: To evaluate hemoglobin A1c (HbA1c) reduction in exenatide and 
liraglutide in a veteran population. METHODS: Retrospective cohort study 
investigating exenatide and liraglutide use in a veteran population over a 24-
month follow-up period. Patients were included if they were >/=18 years, eligible 
for veterans benefits, and initiated exenatide or liraglutide at the Veterans 
Health Administration (VHA). Patients were excluded if they were prescribed 
both medications during the follow-up period or crossed over into the other 
group. Clinical data were extracted from the VHA Corporate Data Warehouse. 
HbA1c reduction was evaluated at 12 months and 24 months. Main dependent 
variable was HbA1c reduction from baseline at 24 months. Multiple linear 
regression evaluated reduction in HbA1c controlling for potential confounders. 
Statistical significance was set at P=.05. RESULTS: A total of 1318 patients were 
identified receiving exenatide (N=1181) and liraglutide (N=137) based on 
inclusion and exclusion criteria. A majority of the exenatide patients were male 
(N=1102, 93%); average age was 59.8 years, average Charlson comorbidity index 
(CCI) was 1.53, and average BMI was 37.53 kg/m2. Similarly, a majority of the 
liraglutide patients were male (N=126, 92%); average age was 62.93 years; average 
CCI was 1.51; and average BMI was 34.68 kg/m2. At 12 months HbA1c reduction 
was significant within the exenatide (P<0.0001) and liraglutide (P<0.0001) groups. 
We observed similar findings at the 24-month follow up. In the multiple linear 
regression, exenatide was associated with an HbA1c reduction of 0.093% (95% 
Confidence Interval (CI): -0.55, 0.74) compared to liraglutide while controlling for 
confounders (R-square=0.37). CONCLUSIONS: These results have important 
implications regarding formulary decisions. Other factors such as dosing 
regimen, adherence, and side effect profile may be important attributes for 
formulary preference. Moreover, evaluating clinical outcomes (e.g., stroke and 
mortality) may reveal important differences. Generalizability may be limited to a 
non-veteran population.  
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OBJECTIVES: To establish a framework assessing effects of multiple drug 
switching patterns, this preliminary study aimed to assess the risk of 
cardiovascular diseases (CVDs) associated with antidiabetic monotherapy 
intervals in type-2 diabetic (T2D) patients. METHODS: This retrospective cohort 
study was conducted from April 2004 to February 2009 using the Taiwan Pay-for-
Performance Diabetes Registry (November 2003 to February 2009), which 
contains clinical indicators and claim records of registered diabetic patients. 
Adult newly-registered T2D patients who initiated antidiabetics from April 2004 
to February 2009 were included. Individuals’ antidiabetic monotherapy intervals 
including metformin, sulphonylureas (SUs), meglitinides (MGs), acarbose, 
pioglitazone, rosiglitazone, and insulin were identified and followed to any 
change of interval, cardiovascular event (i.e. myocardial infarction, ischemic 
heart disease and congestive heart failure) or the end of study. Cox regression 
was used to evaluate CVD risk associated with different interval groups 
comparing against metformin and adjusted for diabetic history (year), gender, 
age, body mass index, blood pressure, triglyceride, and use of anti-hypertensive 
and lipid-controlling drugs. RESULTS: Of the 75,303 newly-registered T2D 
patients without CVDs included in the study, 150,144 intervals and 949 events 
were identified. The mean follow-up duration was 3.9±2.1 years per patient and 
the mean interval period was 238±317 days. Of the seven interval groups, SU 
monotherapy was the most frequently identified and the highest CVD incidence 
group. All interval groups had significantly higher risk of CVDs than metformin, 
the Hazard Ratio (95% confidence interval) for SUs, MGs, acarbose, pioglitazone, 
rosiglitazone, and insulin were 1.563 (1.31, 1.86); 1.38 (1.10, 1.74); 1.56 (1.22, 1.98); 
1.53 (1.19, 1.95); 1.50 (1.18, 1.92); 1.48 (1.20, 1.83), respectively. CONCLUSIONS: The 
results are inconsistent with previous literature comparing CVD risk of acarbose, 
MGs and pioglitazone against metformin. Interval-based CVD risk may be biased 
by the interval definition (monotherapy, multiple-therapy, multiple switching) 
and individual patients’ underline condition.  
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OBJECTIVES: As exenatide QW (EQW) is the first approved GLP-1 receptor agonist 
administered weekly, it is important to understand how this treatment is being 
utilized in patients with type 2 diabetes initiating treatment. The purpose of this 
study is to describe the demographic and clinical characteristics and medication 
patterns of patients initiating EQW in a real-world setting. METHODS: This 
retrospective cohort study used data from the Medical Quality Improvement 
Consortium of ambulatory medical practices that use Centricity Office from GE 
Healthcare IT as their electronic medical record. Patients (n=2,715) receiving a 
prescription for EQW between February 1, 2012 and August 31, 2012 were 
identified. RESULTS: Of patients who initiated EQW, 56% were female, 60% white 
and 32% unknown/other, 69% 40 to 64 y. For patients with data recorded, mean 
BMI was 37 kg/m2, with 16% with BMI subset 20 to <30, 55% with 30 to <40, and 
29% with =>40; 25% had baseline A1C >9%, 34% had 7.5 to <9%, 27% had 6.5 to 
<7.5%, and 15% had <6.5%. Glucose-lowering medications used within 90 days 
before initiating EQW included combination therapy (25%), MET only (11%), 
insulin only (9%), SU only (4%), DPP-IV inhibitor only (3%), and no glucose-
lowering medication (47%).  
Within 9 months prior to initiating EQW, the most common non-diabetes 
comorbid conditions were hyperlipidemia (9%) and hypertension (7%). The most 
common concomitant medications were MET (54%), insulin (needle, 32%), 
lisinopril (20%), insulin glargine (18%), simvastatin (17%), glimepiride (17%), 
liraglutide (16%), levothyroxine sodium (15%), atorvastatin calcium (14%), 
pioglitazone HCL (13%), glipizide (12%), insulin aspart (12%), and rosuvastatin 
calcium (12%). CONCLUSIONS: This study, the first to characterize patients 
treated in routine clinical practice within 6 months after EQW became available 
in the US, indicates that EQW was prescribed to patients across a broad range of 
A1C levels and use of glucose-lowering agents.  
 
PDB18  
PREVALENCE AND INCIDENCE OF ACUTE UROGENITAL CONDITIONS IN A US 
COMMERCIALLY-INSURED POPULATION  
Li Q1, Wu N1, Lee E2, Sullivan PW3 
1United BioSource Corporation, Lexington, MA, USA, 2Boehringer Ingelheim Pharmaceuticals, Inc., 
Ridgefield, CT, USA, 3Regis University School of Pharmacy, Denver, CO, USA  
OBJECTIVES: A retrospective analysis was conducted to compare the prevalence 
and incidence of acute urinary tract infections (UTIs) and genital infections (GIs) 
between adults with type 2 diabetes mellitus (T2DM) versus those without DM 
(no-DM). METHODS: Commercially-insured adults were selected from a large, US 
claims database from 2006-2010. Patients with T2DM were identified via 
diagnosis codes and use of non-insulin, anti-diabetic medications. Prevalence 
and incidence of UTIs (cystitis, urethritis, or acute pyelonephritis) or GIs 
(females: vulvovaginal candidiasis and bacterial vaginosis; males: balanitis) were 
estimated by gender for each calendar year (CY), and averages over CYs were 
reported. Prevalence was defined as the proportion of individuals with 1+ 
medical claim for UTI or GI, and incidence as the number of events over 1000 
person-years, assuming each event lasted ≤ 30 days. Age-adjusted prevalence 
ratio (PR) and incidence rate ratio (IRR) between T2DM vs. no-DM were reported 
with 95% confidence intervals (CIs). RESULTS: 18-30 million individuals with 
T2DM were identified per CY; 6.8% (2006) to 8.8% (2010). Prevalence and 
incidence of UTI among T2DM males were 4.6% and 55.3/1000 person-years and 
were higher among T2DM males than no-DM (PR [95% CI]: 2.23[2.22-2.24]; IRR 
[95% CI]: 2.36[2.35-2.37]). The prevalence and incidence of GIs among T2DM 
males were 0.4% and 4.3/1000 person-years and were higher among T2DM males 
than no-DM (PR: 3.99[3.92-4.05]; IRR: 4.00[3.92-4.07]). Prevalence and incidence of 
UTI among T2DM females were 14.1% and 180.5/1000 person-years, and rates of 
GI were 4.2% and 46.4/1000 person-years. The prevalence and incidence of UTIs 
were higher among T2DM females than no-DM (PR: 1.77[1.77-1.78]; IRR: 1.88[1.87-
1.88]). The prevalence and incidence of GIs were higher among T2DM females 
than no-DM (PR: 1.40[1.40-1.41]; IRR: 1.39[1.38-1.39]). CONCLUSIONS: T2DM was 
positively associated with acute urogenital conditions for both males and 
females.  
